{
    "clinical_study": {
        "@rank": "6654", 
        "acronym": "CP073", 
        "arm_group": {
            "arm_group_label": "intranasal transmucosal fentanyl pectin", 
            "description": "intranasal transmucosal fentanyl in pectin (100, 200,  400 or 800 microg) intranasal route titration phase 7 days treatment phase until completing treatment of 12 consecutive episodes of breakthrough pain"
        }, 
        "brief_summary": {
            "textblock": "An open-label, non-randomized study to assess the titration, safety and efficacy of\n      intranasal fentanyl pectin nasal spray for the treatment of secondary breakthrough pain\n      secondary to radiation-induced mucositis in patients with confirmed tolerance of opioid\n      therapy for chronic pain.\n\n      Study objectives include assessment of breakthrough pain episodes related with food intake\n      in patients with mucositis secondary to radiotherapy or radio-chemotherapy for head and neck\n      tumors"
        }, 
        "brief_title": "Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breakthrough Pain", 
            "Mucositis", 
            "Radiotherapy", 
            "Chemotherapy", 
            "Head and Neck Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Mucositis"
            ]
        }, 
        "detailed_description": {
            "textblock": "An open, non-randomized study design was used to assess the titration, safety and efficacy\n      of intranasal fentanyl in pectin for the treatment of secondary breakthrough pain in\n      patients with confirmed tolerance of opioid therapy for chronic pain secondary to\n      radiation-induced mucositis. The study plans to include 30 evaluable patients from multiple\n      centers throughout the country. The trial comprises a screening period, an open titration\n      period, and an open-label treatment period in which at least 12 breakthrough pain episodes\n      are to be treated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        A histologically confirmed diagnosis of head and neck carcinoma Treatment in the form of\n        radiotherapy or radio-chemotherapy Breakthrough pain related to swallowing (one to four\n        daily episodes) Treatment with controlled release opioids at the time of inclusion: at\n        least 60 mg of morphine sulfate daily, at least 25 microg of transdermal fentanyl per\n        hour, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily\n\n        Exclusion Criteria:\n\n          -  Patients without controlled release opioid treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "adults of either sex and over 18 and under 75 years of age, receiving continued treatment\n        with long half-life or controlled release opioids, experiencing breakthrough pain\n        secondary to mucositis in the context of radiotherapy or radio-chemotherapy for head and\n        neck tumors."
            }
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050503", 
            "org_study_id": "CP073"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fentanyl", 
                "Pectin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mucositis", 
            "Breakthrough pain", 
            "Head Nad neck cancer", 
            "Intranasal transmucosal fentanyl in pectin"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "email": "rafael.moleron@nhs.net", 
                "last_name": "Rafael Moler\u00f3n, MD"
            }, 
            "contact_backup": {
                "email": "atorre.hpth@salud.madrid.org", 
                "last_name": "Alejandro De la Torre, MD", 
                "phone": "+34 91 1916634"
            }, 
            "facility": {
                "address": {
                    "city": "Majadahonda", 
                    "country": "Spain", 
                    "state": "Madrid", 
                    "zip": "28220"
                }, 
                "name": "Alejandro de la Torre. Hospital Puerta de Hierro"
            }, 
            "investigator": [
                {
                    "last_name": "Alejandro De la Torre, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Rafael Moler\u00f3n, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Laura Cerezo, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ana Ruiz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Asuncion Hervas, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ana Ma\u00f1as, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Ability of Intranasal Transmucosal Fentanyl Pectin Nasal Spray to Prevent Breakthrough Pain Episodes in Patients With Radiation-induced Oropharyngeal Mucositis", 
        "other_outcome": {
            "description": "The appearance of adverse effects during the study Physical examination at each visit Vital signs: blood pressure, pulse Concomitant medication for breakthrough pain Reasons for patient study withdrawal (in the event of withdrawal)", 
            "measure": "safety of intranasal transmucosal fentanyl", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "overall_contact": {
            "email": "rafael.moleron@nhs.net", 
            "last_name": "Rafael Moler\u00f3n, MD"
        }, 
        "overall_contact_backup": {
            "email": "atorre.hpth@salud.madrid.org", 
            "last_name": "Alejandro De la Torre"
        }, 
        "overall_official": {
            "affiliation": "GICOR & Hospital Puerta de Hierro", 
            "last_name": "Alejandro De la Torre, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pain Intensity difference: Pain Intensity will be measured 30 min after starting food intake during the screening phase and 30 min after intranasal transmucosal fentanyl in pectin administration/food intake during the treatment phase", 
            "measure": "Pain Intensity Difference", 
            "safety_issue": "No", 
            "time_frame": "30 minutes after PecFent administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050503"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The number of episodes of breakthrough pain requiring additional (rescue) analgesic treatment after administration of the study medication.\nPatient rating of drug efficacy measured on a scale from 0 to 10 (0 = ineffective, 10 = totally effective).\nQuality of life assessed with the European Organization for Research and Treatment of Cancer  quality of life questionnaire -INF025 in its validated Spanish version, administered on the screening visit and at the end of the study.\nPatient rating of drug ease of use measured on a scale from 1 to 4 (1 = very complicated, 4 = very simple).", 
            "measure": "number of episodes of breakthrough pain requiring additional (rescue) analgesic treatment after administration of the study medication", 
            "safety_issue": "No", 
            "time_frame": "12 episodes of breakthrough pain presenting within a maximum of 7 days."
        }, 
        "source": "Grupo de Investigaci\u00f3n Cl\u00ednica en Oncolog\u00eda Radioterapia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grupo de Investigaci\u00f3n Cl\u00ednica en Oncolog\u00eda Radioterapia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}